Bone Biologics Corp

For the period ended Dec 31, 2024. Filed Feb 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 26, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Deficit

Consolidated Statement of Stockholders’ Equity

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2022	63,820	64	77,907,471	(71,960,227)	5,947,308
Fair value of vested stock options	-	-	152,599	-	152,599
Proceeds from sale of common stock in public offering, net of offering costs $684,839	459,643	459	5,043,702	-	5,044,161
Exercise of warrants	10,775	11	(11)	-	-
Extinguishment of warrant liability upon exercise of warrants	-	-	711,024	-	711,024
Net Loss	-	-	-	(8,948,731)	(8,948,731)
Balance at December 31, 2023	534,238	534	83,814,785	(80,908,958)	2,906,361
Fair value of vested stock options	-	-	188,819	-	188,819
Options issued to settle accrued bonus	-	-	77,400	-	77,400
Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs of $495,227	119,000	119	1,503,994	-	1,504,113
Exercise of pre-funded warrants	662,251	662	-	-	662
Issuance of common shares from warrant inducement, net of costs of $287,233	781,251	781	1,805,739	-	1,806,520
Incremental value of warrant inducement	-	-	3,212,504	-	3,212,504
Deemed dividend on warrant inducement	-	-	(3,212,504)	-	(3,212,504)
Issuance of common shares from ATM, net of costs of $205,256	857,242	857	1,111,345	-	1,112,202
Net Loss	-	-	-	(4,112,420)	(4,112,420)
Balance at December 31, 2024	2,953,982	$2,953	$88,502,082	$(85,021,378)	$3,483,657

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.